61532-35-2

Usage

Molecular structure

A phenyl group attached to an imidazo[4,5-c]pyridine ring system.

Type of compound

Heterocyclic aromatic compound.

Potential applications

Medicinal chemistry and drug development.

Known for

Ability to interact with biological targets, such as receptors or enzymes.

Value

Valuable scaffold for the design of novel pharmaceutical agents.

Possible pharmacological properties

Anti-cancer, anti-inflammatory, or antimicrobial activities.

Subject of interest

Further research and investigation in the field of chemical and biological sciences.

Upstream product

• 3473-63-0 formamidine acetic acid 
• 35826-31-4 3-amino-4-(phenylamino)pyridine 
• 35750-90-4 4-(N-phenylamino)-3-nitropyridine 
• 13091-23-1 4-chloro-3-nitropyridine 
• 62-53-3 aniline 
• 64-18-6 formic acid 
• 272-97-9 Imidazo<4,5-c>pyridin 

Downstream Products

• 1078168-14-5 C₁₂H₉N₃O 
• 61531-50-8 1-Phenyl-1,3-dihydro-imidazo[4,5-c]pyridine-2-thione 
• 87673-89-0 1-phenyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 

Relevant academic research and scientific papers

Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor

The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded methyl substituted 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridines ultimately leading to the identification of 1 (JNJ 54166060). 1 is a potent P2X7 antagonist with an ED50 = 2.3 mg/kg in rats, high oral bioavailability and low-moderate clearance in preclinical species, acceptable safety margins in rats, and a predicted human dose of 120 mg of QD. Additionally, 1 possesses a unique CYP profile and was found to be a regioselective inhibitor of midazolam CYP3A metabolism.

P2X7 MODULATORS

The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.

Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1α prolyl hydroxylase-2 inhibitors

We report the structure-based design and synthesis of a novel series of aza-benzimidazoles as PHD2 inhibitors. These efforts resulted in compound 22, which displayed highly potent inhibition of PHD2 function in vitro.

Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor

1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR). Structure- activity relationships (SARs) are narrow, with closely related heterocycles being inactive. A systematic study of